J&J Signs $990M Crohn’s Drug Deal with Protagonist Therapeutics

May 30, 2017

Johnson & Johnson has signed a deal with Protagonist Therapeutics to co-develop and commercialize PTG-200 for inflammatory bowel disease. The worldwide agreement includes a $50 million upfront investment with milestones worth up to $940 million. J&J will get exclusive worldwide licensing rights to Protagonist’s PTG-200.

Protagonist has the drug slated to go into a Phase I trial with healthy patients and then will shift to an IBD study. Protagonist and J&J will then move to co-development through Phase II, but give J&J rights to carry it on from there while Protagonist will still co-detail marketing rights in the United States.

According to an 8-K filing, J&J is paying 80 percent of the development costs.

Read the Reuters brief

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments